List of Excipients in Branded Drug SOFDRA

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Botanix SB Inc	SOFDRA	sofpironium bromide	83723-010	ALCOHOL	2029-06-20
Botanix SB Inc	SOFDRA	sofpironium bromide	83723-010	CITRIC ACID MONOHYDRATE	2029-06-20
Botanix SB Inc	SOFDRA	sofpironium bromide	83723-010	HEXYLENE GLYCOL	2029-06-20
Botanix SB Inc	SOFDRA	sofpironium bromide	83723-010	HYDROXYPROPYL CELLULOSE	2029-06-20

SOFDRA Excipient Strategy and Commercial Opportunities in Hyperhidrosis Treatment

Last updated: August 29, 2026

SOFDRA is a once-daily topical gel containing 12.45% sofpironium bromide for primary axillary hyperhidrosis in adults and patients aged 9 years and older. Its excipient system is built around a carbomer gel, diethylene glycol monoethyl ether as a solvent and penetration aid, propylene glycol, methylparaben, purified water, and sodium hydroxide for pH adjustment. The commercial opportunity is concentrated in tolerability, adherence, packaging, site expansion, and differentiated formulations rather than in creating a new active ingredient. [1]

What is SOFDRA and how does its formulation work?

SOFDRA is a topical anticholinergic gel developed by Journey Medical Corporation and approved by the FDA in June 2024 under NDA 214801. Its active ingredient, sofpironium bromide, is a competitive antagonist of muscarinic acetylcholine receptors. By reducing cholinergic stimulation of eccrine sweat glands, it lowers sweat production at the application site. [1,2]

The approved product is not a cream. It is a nonsterile, water-based topical gel supplied for application to the axillae once daily.

Attribute	SOFDRA
Active ingredient	Sofpironium bromide
Strength	12.45%
Dosage form	Topical gel
Indication	Primary axillary hyperhidrosis
Patient population	Adults and patients 9 years and older
Application	Once daily to each axilla
Sponsor	Journey Medical Corporation
FDA approval	June 2024
Application number	NDA 214801
Route	Topical
Pharmacologic class	Anticholinergic

The product addresses a large treatment gap between prescription antiperspirants, topical anticholinergic wipes, oral anticholinergics, botulinum toxin injections, and surgical interventions.

What excipients are used in SOFDRA?

The FDA prescribing information identifies six inactive ingredients in SOFDRA: carbomer 980, diethylene glycol monoethyl ether, methylparaben, propylene glycol, purified water, and sodium hydroxide. [1]

Excipient	Likely formulation function	Commercial relevance
Carbomer 980	Gelling and viscosity control	Controls spreadability, residence time, and dose uniformity
Diethylene glycol monoethyl ether	Solvent and penetration-enhancing vehicle	Supports drug solubilization and topical delivery
Methylparaben	Preservative	Supports microbiological quality in a multidose aqueous product
Propylene glycol	Solvent, humectant, and co-solvent	Supports solubility and skin wetting
Purified water	Primary vehicle	Determines hydration, viscosity, and microbial-control requirements
Sodium hydroxide	pH adjustment and carbomer neutralization	Controls gel formation, viscosity, and skin compatibility

The formulation strategy is conventional in excipient selection but commercially effective. Carbomer provides a recognizable gel structure, while the solvent system supports delivery of a relatively high concentration of an anticholinergic active ingredient.

Why is the SOFDRA excipient system commercially important?

The excipients influence four commercial variables: drug delivery, local tolerability, patient adherence, and manufacturing cost.

Diethylene glycol monoethyl ether, commonly known as Transcutol-type solvent technology, can improve the solubility and dermal delivery of active pharmaceutical ingredients. Its use may also help produce a clear or uniform gel with acceptable application properties. The tradeoff is that solvent concentration can affect stinging, erythema, dryness, and barrier disruption.

Propylene glycol has a similar dual role. It can improve wetting and solubilization, but it is also associated with irritation or sensitization in some topical products. In a chronic-use product for hyperhidrosis, tolerability can determine prescription persistence more than the pharmacologic mechanism.

Carbomer 980 controls viscosity and residence time. A gel that is too fluid may run, transfer to clothing, or deliver inconsistent doses. A gel that is too viscous may be difficult to spread and may leave residue. The selected polymer therefore has a direct relationship to patient experience and refill behavior.

Methylparaben supports preservation in a water-containing multidose product. A preservative-free version could have commercial appeal, but it would require an alternative microbiological-control strategy, such as a single-use package, airless pump, sterile manufacturing approach, or validated low-bioburden container system.

What formulation patents could protect SOFDRA-like products?

A drug product’s commercial protection can involve the active compound, formulation, manufacturing process, dosage form, delivery system, and method of use. Public FDA labeling establishes the approved composition and use but does not, by itself, establish the complete patent estate.

Potential formulation claim categories for a sofpironium product include:

1. A specified concentration range of sofpironium bromide.
2. A carbomer-based topical gel with defined viscosity or rheology.
3. A solvent system containing diethylene glycol monoethyl ether and propylene glycol.
4. Defined pH ranges that maintain drug stability and gel performance.
5. Preserved aqueous formulations with specified methylparaben concentrations.
6. Low-irritation formulations that reduce erythema or burning.
7. Packaging systems that limit evaporation, contamination, or dose variability.
8. Manufacturing processes for dissolving, neutralizing, and homogenizing the gel.
9. Methods of treating axillary hyperhidrosis with once-daily topical sofpironium.
10. Use in pediatric patients or in nonaxillary hyperhidrosis.

The strongest formulation claims generally require more than a simple list of commercially available excipients. Their durability may depend on unexpected stability, delivery, tolerability, or clinical results. A composition that merely substitutes one standard solvent or preservative for another may face obviousness challenges if the change produces predictable results.

What excipient opportunities exist for SOFDRA line extensions?

The clearest opportunities concern reduced irritation, improved convenience, and expanded anatomical use.

Preservative-free SOFDRA

A preservative-free gel could target patients who experience irritation or who prefer products without parabens. The main technical issue is packaging. A multidose aqueous product needs protection from microbial contamination during repeated use. Single-dose sachets, unit-dose tubes, or an airless pump could support a preservative-free presentation.

The opportunity is commercially meaningful but may increase packaging cost, shipping volume, and patient handling complexity.

Lower-solvent formulation

A lower concentration of diethylene glycol monoethyl ether or propylene glycol could reduce irritation and improve use on sensitive skin. The challenge is maintaining solubility, drug release, gel uniformity, and shelf stability at the same active concentration.

This strategy could generate a differentiated formulation patent if clinical testing shows lower dermatitis rates without sacrificing efficacy.

Sensitive-skin gel

A sensitive-skin version could use a narrower excipient profile, lower solvent load, altered pH, and a different polymer grade. The target population would include patients who discontinue topical anticholinergics because of local adverse reactions.

The product would need clinical or human-factors evidence to support meaningful differentiation. A simple “gentle” positioning claim would not provide the same value as demonstrated reductions in irritation or discontinuation.

Fast-drying formulation

A fast-drying gel could improve adherence by reducing transfer to clothing and shortening the time between application and dressing. Potential approaches include modified polymer concentration, volatile co-solvents, sprayable gels, or packaging that delivers a thinner film.

The formulation must avoid excessive evaporation that changes delivered dose or creates local drug crystallization.

Non-gel delivery systems

Alternative dosage forms could include:

• Topical foam
• Pumped emulsion
• Sprayable solution
• Film-forming liquid
• Medicated wipe
• Hydrogel patch
• Single-use applicator

A wipe would directly compete with Qbrexza, which uses glycopyrronium tosylate in a premoistened cloth. A foam or spray could improve application speed but would introduce additional requirements for dose uniformity, flammability, container compatibility, and actuation performance.

How does SOFDRA compare with competing hyperhidrosis products?

SOFDRA competes across several treatment categories rather than against one product.

Product or treatment	Active or modality	Dosage form	Key differentiation
SOFDRA	Sofpironium bromide	Once-daily gel	Axillary topical anticholinergic for patients 9 and older
Qbrexza	Glycopyrronium tosylate	Once-daily cloth	Premeasured wipe; competing topical anticholinergic
Drysol and generic aluminum chloride	Aluminum chloride	Solution or antiperspirant	Low-cost, established first-line option; irritation can limit use
Oral glycopyrrolate	Glycopyrrolate	Tablet	Systemic treatment; broader exposure and systemic anticholinergic effects
Botox	OnabotulinumtoxinA	Injection	High efficacy with procedural administration and temporary duration
Iontophoresis	Electrical treatment	Device-based	Particularly used for palms and soles
Surgery	Sympathectomy or related procedures	Procedure	Invasive option for severe refractory disease

SOFDRA’s main commercial advantage is a once-daily gel that avoids the administration burden of injections and the systemic exposure associated with oral anticholinergics. Its main competitive risks are local irritation, anticholinergic class effects from unintended transfer or exposure, and lower-cost generic antiperspirants.

What FDA regulatory status and exclusivity apply to SOFDRA?

SOFDRA received FDA approval for primary axillary hyperhidrosis in June 2024. The approved label includes warnings concerning unintended exposure to the eyes, accidental transfer, urinary retention, blurred vision, and other anticholinergic effects. [1]

The FDA approval provides regulatory exclusivity associated with the new drug application. The exact scope and duration of market exclusivity must be evaluated against the FDA Orange Book and any listed patents. The approval itself does not establish five-year new chemical entity exclusivity for sofpironium bromide. Public product materials identify sofpironium bromide as the active ingredient, while the commercial product’s exclusivity position depends on FDA classification, prior approvals in relevant jurisdictions, and listed patent rights.

The principal regulatory pathways for competitors are likely to include:

• Abbreviated New Drug Applications if a qualifying reference-product pathway is available.
• Section 505(b)(2) applications for products with changes in dosage form, excipients, strength, or route.
• Full 505(b)(1) applications for materially different clinical or pharmacologic products.
• Product-specific development programs for alternative topical dosage forms.

A reformulated product with the same active ingredient could face a 505(b)(2) pathway rather than a conventional ANDA if the proposed formulation differs materially from the reference product.

When does SOFDRA lose exclusivity and face generic entry?

No single date determines SOFDRA’s loss of exclusivity. Generic entry depends on FDA regulatory exclusivity, listed patents, patent certifications, litigation, and any settlement restrictions.

Paragraph IV risk

A generic applicant could file a Paragraph IV certification against listed patents by asserting that the patent is invalid, unenforceable, or not infringed. If the sponsor brings suit within the statutory period, FDA approval may be subject to a 30-month stay, subject to court and regulatory developments.

Potential Paragraph IV targets could include patents covering:

• The sofpironium bromide composition.
• The 12.45% topical gel.
• The carbomer and solvent system.
• The method of treating axillary hyperhidrosis.
• Pediatric treatment.
• Packaging or application systems.

Simple excipient substitutions may create a design-around path if the relevant claims are narrow. Broad claims covering the active ingredient or core method of treatment would be more difficult to avoid.

Generic launch scenarios

Scenario	Likely commercial effect
Patent litigation with no settlement	Delayed generic entry and continued branded pricing
Early settlement with an agreed entry date	Predictable erosion after the settlement date
Narrow formulation patent estate	Increased risk from alternative topical formulations
Broad active-ingredient or method claims	Lower near-term generic risk
505(b)(2) reformulation	Potential competition before conventional generic substitution
OTC or nonprescription competitor	Possible pricing pressure without direct AB-rated substitution

How strong is the SOFDRA patent estate?

The patent estate should be viewed in layers. Composition-of-matter protection for the active ingredient is generally stronger than formulation protection, but its value depends on claim scope and expiration. Formulation patents can be commercially important when they cover the approved concentration, excipient ratios, viscosity, pH, or delivery system. Method-of-use patents can support enforcement against products labeled for the same indication, although induced-infringement and labeling issues can affect litigation outcomes.

For SOFDRA, the highest-value IP areas are likely to be:

1. The sofpironium molecule and salt form.
2. The approved topical concentration.
3. The gel vehicle and solvent system.
4. The once-daily axillary treatment method.
5. Pediatric use.
6. Packaging and dosing controls.

The excipient estate is potentially valuable but vulnerable if claims rely only on routine ingredients at predictable levels. Stronger protection would require a defined relationship between composition and an unexpected result, such as improved skin tolerability, greater drug release, longer residence time, or better stability.

What manufacturing and IP barriers affect SOFDRA competitors?

Manufacturing a commercial sofpironium gel involves more than blending the listed ingredients. Key process controls include:

• Complete dissolution or uniform dispersion of sofpironium bromide.
• Consistent carbomer hydration.
• Controlled sodium hydroxide addition and neutralization.
• Batch-to-batch viscosity control.
• Uniform active concentration throughout the batch.
• Microbial-control validation.
• Container compatibility and extractables testing.
• Stability under temperature and humidity stress.
• Consistent delivered dose from the commercial package.

A competitor may be able to use different excipients, but it must still demonstrate stability, preservative effectiveness, drug release, skin permeation, and acceptable irritation. These requirements create development barriers even when the formulation ingredients are individually available from multiple suppliers.

What licensing and commercial opportunities exist around SOFDRA?

The most attractive licensing opportunities are adjacent to the approved product rather than direct replication of the exact gel.

Potential deal areas include:

• Regional commercialization rights outside the United States.
• Pediatric and adolescent market development.
• Nonaxillary hyperhidrosis, including palmar, plantar, craniofacial, or generalized disease.
• Preservative-free packaging.
• Sensitive-skin reformulation.
• Alternate delivery systems.
• Contract manufacturing of topical gels.
• Digital adherence and refill programs.
• Co-promotion with dermatology-focused companies.
• Combination treatment with non-anticholinergic hyperhidrosis therapies.

A reformulated product that reduces local irritation or improves application could support a lifecycle-management transaction. A nonaxillary indication would require clinical evidence and could face greater systemic exposure concerns because of larger application areas.

What revenue exposure does SOFDRA create for Journey Medical?

SOFDRA’s revenue opportunity depends on diagnosis rates, dermatology prescribing, reimbursement, refill persistence, and competition from Qbrexza and low-cost aluminum chloride products. Hyperhidrosis is commonly underdiagnosed, so market expansion depends on physician recognition and patient willingness to seek treatment.

The product’s commercial model has several advantages:

• Chronic-use indication supports recurring prescriptions.
• Once-daily administration supports refill demand.
• Topical delivery may appeal to patients avoiding injections or oral therapy.
• Pediatric approval expands the addressable population.
• Dermatology distribution aligns with Journey Medical’s commercial capabilities.

The main revenue constraints are likely to be formulary access, copay burden, local tolerability, and patient substitution with inexpensive antiperspirants.

Key Takeaways

• SOFDRA is a 12.45% sofpironium bromide topical gel approved in June 2024 for primary axillary hyperhidrosis in adults and patients aged 9 years and older.
• Its excipient system contains carbomer 980, diethylene glycol monoethyl ether, methylparaben, propylene glycol, purified water, and sodium hydroxide.
• The main excipient opportunity is improved tolerability, particularly through preservative-free, lower-solvent, sensitive-skin, or fast-drying formulations.
• Formulation patents may be valuable but are more vulnerable to invalidity and design-around arguments than broad composition-of-matter claims.
• Competitors may pursue ANDA or 505(b)(2) strategies depending on the formulation and regulatory pathway.
• Key commercial competitors include Qbrexza, aluminum chloride products, oral anticholinergics, botulinum toxin, iontophoresis, and surgery.
• The strongest lifecycle opportunities are nonaxillary indications, pediatric development, alternative packaging, and differentiated topical delivery systems.
• Generic-entry timing depends on FDA exclusivity, Orange Book listings, patent litigation, Paragraph IV certifications, and settlements.

FAQs

Can SOFDRA be reformulated without using carbomer 980?

Yes. A competitor could evaluate other carbomer grades, cellulose polymers, poloxamers, acrylic copolymers, or film-forming systems. The substitute must preserve drug uniformity, viscosity, stability, release, and skin tolerability.

Is SOFDRA a cream or a gel?

SOFDRA is a topical gel. The FDA-approved product contains 12.45% sofpironium bromide in a carbomer-based aqueous vehicle. [1]

Could a preservative-free SOFDRA product be commercially viable?

Yes. A preservative-free product would likely require unit-dose packaging, an airless dispenser, or another validated contamination-control system. Its commercial value would depend on lower irritation and improved adherence.

Does SOFDRA compete directly with Qbrexza?

Yes. Both are topical anticholinergic treatments for axillary hyperhidrosis. SOFDRA is a gel, while Qbrexza is a premoistened cloth containing glycopyrronium tosylate.

What is the most defensible excipient patent strategy for a SOFDRA competitor?

The strongest strategy would connect a defined excipient composition to measurable advantages, such as reduced irritation, improved stability, enhanced delivery, controlled drying, or superior dose uniformity. A patent based solely on replacing one routine solvent or polymer with another would face greater validity risk.

References

1. U.S. Food and Drug Administration. (2024). SOFDRA (sofpironium) topical gel, 12.45% prescribing information. Journey Medical Corporation.

2. U.S. Food and Drug Administration. (2024, June 18). FDA approves new treatment for excessive underarm sweating. https://www.fda.gov

3. U.S. Food and Drug Administration. (2024). Drugs@FDA: SOFDRA, NDA 214801. https://www.accessdata.fda.gov/scripts/cder/daf/

4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.fda.gov/drugsatfda